Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but KarXT is one of a clutch of new therapies emerging from the pharma ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

“Securing this patent strengthens our intellectual property portfolio, continuing progress on naronapride’s global clinical development,” said Dr. Peter Milner, M.D., FACC, Chairman and CEO of ...

New Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...